Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase

British Journal of Haematology

Volumn 158, Issue 5, 2012, Pages 608-614

  Muringampurath John, Disni ^a   Jaye, David L ^a   Flowers, Christopher R ^a   Saxe, Debra ^a   Chen, Zhengjia ^a   Lechowicz, Mary J ^a   Weisenburger, Dennis D ^b   Bast, Martin ^c   Arellano, Martha L ^a   Bernal Mizrachi, Leon ^a   Heffner, Leonard T ^a   Mclemore, Morgan ^a   Kaufman, Jonathan L ^a   Winton, Elliott F ^a   Lonial, Sagar ^a   Armitage, James O ^c   Khoury, Hanna J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Characteristics; Diffuse large B cell lymphoma; Leukaemic phase; Outcomes; Treatment

Indexed keywords

ANTHRACYCLINE; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FMC7 PROTEIN; HLA DR ANTIGEN; IFOSFAMIDE; LACTATE DEHYDROGENASE; LYMPHOCYTE ANTIGEN; METHOTREXATE; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; DOSE RESPONSE; DRUG FATALITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LARGE CELL LYMPHOMA; LEUKEMIA; LEUKOCYTOSIS; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TUMOR LYSIS SYNDROME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; TREATMENT OUTCOME;

EID: 84865149544     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09209.x     Document Type: Article

References (28)

1. Bain, B.J. & Catovsky, D. (1995) The leukaemic phase of non-Hodgkin's lymphoma. Journal of Clinical Pathology, 48, 189-193.
2. Berinstein, N.L., Reis, M.D., Ngan, B.Y., Sawka, C.A., Jamal, H.H. & Kuzniar, B. (1993) Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early-stage and advanced-stage follicular lymphoma. Journal of Clinical Oncology, 11, 1344-1352.
3. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
4. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235-242.
5. Come, S.E., Jaffe, E.S., Andersen, J.C., Mann, R.B., Johnson, B.L., DeVita, V.T.Jr. & Young, R.C. (1980) Non-Hodgkin's lymphomas in leukemic phase: clinicopathologic correlations. American Journal of Medicine, 69, 667-674.
6. Criel, A., Pittaluga, S., Verhoef, G., Wlodarska, I., Meeus, P., Mecucci, C., Van Orshoven, A., Van den Berghe, H., Boogaerts, M. & De Wolf-Peeters, C. (1996) Small B cell NHL and their leukemic counterpart: differences in subtyping and assessment of leukemic spread. Leukemia, 10, 848-853.
7. De Paepe, P. & De Wolf-Peeters, C. (2007) Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia, 21, 37-43.
8. Drillenburg, P. & Pals, S.T. (2000) Cell adhesion receptors in lymphoma dissemination. Blood, 95, 1900-1910.
9. Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Ferme, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F. & Coiffier, B. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 23, 4117-4126.
10. Flowers, C.R., Sinha, R. & Vose, J.M. (2010) Improving outcomes for patients with diffuse large B-cell lymphoma. CA: A Cancer Journal for Clinicians, 60, 393-408.
11. Gascoyne, R.D., Rosenwald, A., Poppema, S. & Lenz, G. (2010) Prognostic biomarkers in malignant lymphomas. Leukaemia & Lymphoma, 51 (Suppl 1), 11-19.
12. Hong, J., Park, S., Park, J., Kim, H.S., Kim, K.H., Ahn, J.Y., Rim, M.Y., Jung, M., Sym, S.J., Cho, E.K., Shin, D.B. & Lee, J.H. (2011) Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy. Leukaemia & Lymphoma, 52, 1904-1912.
13. Jaffe, E.S. (2009) The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology/The Education Program of the American Society of Hematology. American Society of Hematology. Education Program, ??????, 523-531.
14. Kaplan, E.L. & Meier, P. (1958) Nonparametric-estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
15. Maruyama, D., Watanabe, T., Maeshima, A.M., Nomoto, J., Taniguchi, H., Azuma, T., Mori, M., Munakata, W., Kim, S.W., Kobayashi, Y., Matsuno, Y. & Tobinai, K. (2010) Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. International Journal of Hematology, 92, 732-743.
16. Matos, D.M., Rizzatti, E.G., Garcia, A.B., Gallo, D.A. & Falcao, R.P. (2006) Adhesion molecule profiles of B-cell non-Hodgkin's lymphomas in the leukemic phase. Brazilian Journal of Medical and Biological Research, 39, 1349-1355.
17. Mintzer, D.M. & Hauptman, S.P. (1983) Lymphosarcoma cell leukemia and other non-Hodgkin's lymphomas in leukemic phase. American Journal of Medicine, 75, 110-120.
18. Morra, E., Lazzarino, M., Orlandi, E., Pagnucco, G., Brusamolino, E., Castello, A., Inverardi, D. & Bernasconi, C. (1984) Leukemic phase of non-Hodgkin's lymphomas. Hematological features and prognostic significance. Haematologica, 69, 15-29.
19. Morra, E., Lazzarino, M., Castello, A., Inverardi, D., Coci, A., Pagnucco, G., Orlandi, E., Merante, S., Magrini, U., Zei, G. & Bernasconi, C. (1989) Bone marrow and blood involvement by non-Hodgkin's lymphoma: a study of clinicopathologic correlations and prognostic significance in relationship to the Working Formulation. European Journal of Haematology, 42, 445-453.
20. Muringampurath-John, D., Flowers, C.R., Toscano, M., Zhengjia, C., Kaufman, J.L., Arellano, M., Bernal-Mizrachi, L., Heffner, L.T., Lechowicz, M.J., McLemore, M., Winton, E., Jaye, D.L., Lonial, S. & Khoury, H.J. (2012) Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma. Leukaemia & Lymphoma, 53, 725-727.
21. Nogai, H., Dorken, B. & Lenz, G. (2011) Pathogenesis of non-Hodgkin's lymphoma. Journal of Clinical Oncology, 29, 1803-1811.
22. Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, R.I., Gascoyne, R.D., Muller-Hermelink, H.K., Smeland, E.B., Giltnane, J.M., Hurt, E.M., Zhao, H., Averett, L., Yang, L., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Powell, J., Duffey, P.L., Longo, D.L., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, B.J., Lynch, J.C., Vose, J., Armitage, J.O., Montserrat, E., Lopez-Guillermo, A., Grogan, T.M., Miller, T.P., LeBlanc, M., Ott, G., Kvaloy, S., Delabie, J., Holte, H., Krajci, P., Stokke, T. & Staudt, L.M. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 1937-1947.
23. Schwartz, D.L., Pierre, R.V., Scheerer, P.P., Reed, E.C.Jr. & Linman, J.W. (1965) Lymphosarcoma cell leukemia. American Journal of Medicine, 38, 778-786.
24. Shenoy, P.J., Malik, N., Nooka, A., Sinha, R., Ward, K.C., Brawley, O.W., Lipscomb, J. & Flowers, C.R. (2011) Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer, 117, 2530-2540.
25. Shipp, M.A., Ross, K.N., Tamayo, P., Weng, A.P., Kutok, J.L., Aguiar, R.C., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G.S., Ray, T.S., Koval, M.A., Last, K.W., Norton, A., Lister, T.A., Mesirov, J., Neuberg, D.S., Lander, E.S., Aster, J.C. & Golub, T.R. (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Medicine, 8, 68-74.
26. Sieniawski, M., Bhartia, S., Wilkinson, J. & Proctor, S.J. (2009) Incidence and outcome of patients with diffuse large B cell lymphoma with marrow involvement and preliminary experience of an adult acute lymphoblastic leukemia protocol (NEALL VI) in cyclophosphamide, doxorubicin, vincristine, and prednisolone-rituximab refractory patients. Leukaemia & Lymphoma, 50, 1726-1730.
27. The Non-Hodgkin's Lymphoma Classification Project(1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood, 89, 3909-3918.
28. Villamor, N., Rozman, M., Esteve, J., Aymerich, M., Colomer, D., Aguilar, J.L., Campo, E. & Montserrat, E. (1999) Anaplastic large-cell lymphoma with rapid evolution to leukemic phase. Annals of Hematology, 78, 478-482.